XACIATO™ for the treatment of Bacterial vaginosis – 12/5/23

by matt | Dec 5, 2023 | Emails

US-XAC-110130   Learn more about XACIATO     Bacterial vaginosis (BV) can be embarrassing for patients. XACIATOTM (clindamycin phosphate) vaginal gel 2%, a single-dose treatment for BV in females 12 years of age and older, is available in pharmacies....

Permanent J-Code for RYSTIGGO® (rozanolixizumab-noli): Available January 1, 2024 – 11/30/23

by matt | Nov 30, 2023 | Emails

*Corrected* Permanent J-Code for RYSTIGGO® (rozanolixizumab-noli): Available January 1, 2024 Corrected WAC Pricing Effective for claims on or after January 1, 20241:J9333Injection, rozanolixizumab-noli, 1 mg RYSTIGGO (rozanolixizumab-noli) is the first and only...

VABYSMO® (faricimab-svoa): New Indication Now Approved – 11/6/23

by matt | Nov 14, 2023 | Emails

VABYSMO® (faricimab-svoa): New Indication Now Approved Learn what this means for your members and plan VAB RVO Announcement 96 Preheader text here--> View in browser Important Safety Information Prescribing Information Now approved for your members with Macular Edema...

Samsung Bioepis Biosimilar Market Report 3rd Edition, Q4 2023 – 10/10/23

by matt | Oct 10, 2023 | Emails

Samsung Bioepis Biosimilar Market Report 3rd Edition, Q4 2023   SAMSUNG BIOEPISBiosimilar Market Report3rd Edition, Q4 2023 Download Here I. US Biosimilars Approval and Launch StatusII. Biosimilar Price- Medical BenefitOncologySupportive CareImmunology &...

Setmelanotide as a Protein replacement agent: USP Medicare Modeling Guidelines – 10/5/23

by matt | Oct 5, 2023 | Emails

Setmelanotide as a Protein replacement agent: USP Medicare Modeling Guidelines On September 29th, The United States Pharmacopeia (USP) issued the Medicare Modeling Guidelines (MMG) version 9.0 including setmelanotide as a Protein replacement agent Read the USP 9.0...